Replies to post #210558 on Biotech Values

[DewDiligence]

ONVO -39% on this gem in FY4Q19 PR:

https://finance.yahoo.com/news/organovo-updates-key-clinical-development-200500692.html

“We have determined that we need to conduct additional preclinical studies, optimize our manufacturing processes, and most importantly to generate decisive scientific data regarding the prolonged functionality and therapeutic benefits of our liver tissue patch,” said Taylor J. Crouch, CEO, Organovo.

Those with a long memory may know that Crouch was the CEO of Variagenics.